Graeme Martin, PhD
Principal, HatchBox Bioconsulting, LLC
Graeme Martin is a pharmaceutical industry veteran with more than 35 years of multinational Pharma and Biotech R&D experience in Europe, USA and Japan. Currently an independent consultant, he was for 12 years President & CEO of Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd. where he oversaw strategic investments totaling >$100mm into a portfolio 31 early stage companies. He served on the Board of 16 of these companies. Prior to this, he held senior management positions at Telik, Inc., a Bay Area oncology biotech, and from 1996-2001, was with Roche Palo Alto, where he was VP of CNS Research USA. Before moving to the USA, Dr. Martin was a senior research manager at GlaxoWellcome and Wellcome Research Laboratories in the UK. During his R&D career, he has led a number of therapeutic discovery initiatives resulting in three IND submissions and ultimately, the launch of Zomig®, marketed worldwide for the acute treatment of migraine. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.
End of main page content.